1
|
Yssartier T, Liu L, Pardoue S, Le Questel JY, Guérard F, Montavon G, Galland N. In vivo stability of 211At-radiopharmaceuticals: on the impact of halogen bond formation. RSC Med Chem 2024; 15:223-233. [PMID: 38283213 PMCID: PMC10809332 DOI: 10.1039/d3md00579h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Accepted: 11/22/2023] [Indexed: 01/30/2024] Open
Abstract
211At, when coupled to a targeting agent, is one of the most promising radionuclides for therapeutic applications. The main labelling approach consists in the formation of astatoaryl compounds, which often show a lack of in vivo stability. The hypothesis that halogen bond (XB) interactions with protein functional groups initiate a deastatination mechanism is investigated through radiochemical experiments and DFT modelling. Several descriptors agree on the known mechanism of iodoaryl substrates dehalogenation by iodothyronine deiodinases, supporting the higher in vivo dehalogenation of N-succinimidyl 3-[211At]astatobenzoate (SAB) conjugates in comparison with their iodinated counterparts. The guanidinium group in 3-[211At]astato-4-guanidinomethylbenzoate (SAGMB) prevents the formation of At-mediated XBs with the selenocysteine active site in iodothyronine deiodinases. The initial step of At-aryl bond dissociation is inhibited, elucidating the better in vivo stability of SAGMB conjugates compared with those of SAB. The impact of astatine's ability to form XB interactions on radiopharmaceutical degradation may not be limited to the case of aryl radiolabeling.
Collapse
Affiliation(s)
- Thibault Yssartier
- CNRS, CEISAM UMR 6230, Nantes Université F-44000 Nantes France
- CNRS, SUBATECH UMR 6457, IMT Atlantique F-44307 Nantes France
| | - Lu Liu
- CNRS, IPHC UMR 7178, Université de Strasbourg F-67037 Strasbourg France
| | - Sylvain Pardoue
- CNRS, SUBATECH UMR 6457, IMT Atlantique F-44307 Nantes France
| | | | - François Guérard
- Inserm UMR 1307, CNRS UMR 6075, CRCI2NA, Nantes Université, Université d'Angers F-44000 Nantes France
| | - Gilles Montavon
- CNRS, SUBATECH UMR 6457, IMT Atlantique F-44307 Nantes France
| | - Nicolas Galland
- CNRS, CEISAM UMR 6230, Nantes Université F-44000 Nantes France
| |
Collapse
|
2
|
McIntosh LA, Burns JD, Tereshatov EE, Muzzioli R, Hagel K, Jinadu NA, McCann LA, Picayo GA, Pisaneschi F, Piwnica-Worms D, Schultz SJ, Tabacaru GC, Abbott A, Green B, Hankins T, Hannaman A, Harvey B, Lofton K, Rider R, Sorensen M, Tabacaru A, Tobin Z, Yennello SJ. Production, isolation, and shipment of clinically relevant quantities of astatine-211: A simple and efficient approach to increasing supply. Nucl Med Biol 2023; 126-127:108387. [PMID: 37837782 DOI: 10.1016/j.nucmedbio.2023.108387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Revised: 09/04/2023] [Accepted: 09/18/2023] [Indexed: 10/16/2023]
Abstract
The alpha emitter astatine-211 (211At) is a promising candidate for cancer treatment based on Targeted Alpha (α) Therapy (TAT). A small number of facilities, distributed across the United States, are capable of accelerating α-particle beams to produce 211At. However, challenges remain regarding strategic methods for shipping 211At in a form adaptable to advanced radiochemistry reactions and other uses of the radioisotope. PURPOSE Our method allows shipment of 211At in various quantities in a form convenient for further radiochemistry. PROCEDURES For this study, a 3-octanone impregnated Amberchrom CG300M resin bed in a column cartridge was used to separate 211At from the bismuth matrix on site at the production accelerator (Texas A&M) in preparation for shipping. Aliquots of 6 M HNO3 containing up to ≈2.22 GBq of 211At from the dissolved target were successfully loaded and retained on columns. Exempt packages (<370 MBq) were shipped to a destination radiochemistry facility, University of Texas MD Anderson Cancer Center, in the form of a convenient air-dried column. Type A packages have been shipped overnight to University of Alabama at Birmingham. MAIN FINDINGS Air-dried column hold times of various lengths did not inhibit simple and efficient recovery of 211At. Solution eluted from the column was sufficiently high in specific activity to successfully radiolabel a model compound, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1), with 211At. The method to prepare and ship 211At described in this manuscript has also been used to ship larger quantities of 211At a greater distance to University of Alabama at Birmingham. PRINCIPAL CONCLUSIONS The successful proof of this method paves the way for the distribution of 211At from Texas A&M University to research institutions and clinical oncology centers in Texas and elsewhere. Use of this simple method at other facilities has the potential increase the overall availability of 211At for preclinical and clinical studies.
Collapse
Affiliation(s)
- Lauren A McIntosh
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA.
| | - Jonathan D Burns
- Chemistry Department, The University of Alabama at Birmingham, Birmingham, AL 35924, USA.
| | | | - Riccardo Muzzioli
- Department of Cancer System Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Kris Hagel
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA
| | - Noimat A Jinadu
- Chemistry Department, The University of Alabama at Birmingham, Birmingham, AL 35924, USA
| | - Laura A McCann
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Gabriela A Picayo
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Federica Pisaneschi
- Department of Cancer System Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM) at The University of Texas Health Science Center at Houston, USA
| | - David Piwnica-Worms
- Department of Cancer System Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Steven J Schultz
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Gabriel C Tabacaru
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA
| | - Austin Abbott
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Brooklyn Green
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Travis Hankins
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Andrew Hannaman
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Bryan Harvey
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Physics Department, Texas A&M University, College Station, TX 77843, USA
| | - Kylie Lofton
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Robert Rider
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Maxwell Sorensen
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Alexandra Tabacaru
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA
| | - Zachary Tobin
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| | - Sherry J Yennello
- Cyclotron Institute, Texas A&M University, College Station, TX 77843, USA; Chemistry Department, Texas A&M University, College Station, TX 77843, USA
| |
Collapse
|
3
|
Feng Y, Sarrett SM, Meshaw RL, Vaidyanathan G, Cornejo MA, Zeglis BM, Zalutsky MR. Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent. J Med Chem 2022; 65:15358-15373. [PMID: 36368007 DOI: 10.1021/acs.jmedchem.2c01331] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Because of their rapid tumor accumulation and normal tissue clearance, single-domain antibody fragments (sdAbs) are an attractive vehicle for developing radiotherapeutics labeled with the α-emitter 211At. Herein, we have evaluated iso-[211At]AGMB-PODS, a prosthetic agent that combines a functionality for residualizing radiohalogens with a phenyloxadiazolyl methylsulfone (PODS) moiety for site-specific sdAb conjugation. Iso-[211At]AGMB-PODS and its radioiodinated analogue were evaluated for thiol-selective conjugation to anti-HER2 5F7 sdAb bearing a C-terminus GGC tail. Both radiohalogenated PODS-5F7GGC conjugates were synthesized in good radiochemical yields and retained high binding affinity on HER2-positive BT474 breast carcinoma cells. Iso-[211At]AGMB-PODS-5F7GGC was considerably more stable in vitro than its maleimide analogue in the presence of cysteine and human serum albumin (HSA) and exhibited excellent tumor uptake and high in vivo stability. Superior tumor-to-kidney activity ratios were seen for both radiohalogenated PODS-5F7GGC conjugates compared with [177Lu]Lu-DOTA-PODS-5F7GGC. These results suggest that iso-[211At]AGMB-PODS-5F7GGC warrants further evaluation for the treatment of HER2-expressing malignancies.
Collapse
Affiliation(s)
- Yutian Feng
- Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, United States
| | - Samantha M. Sarrett
- Hunter College, City University of New York, New York, New York 10021, United States
- Ph.D. Programs in Biochemistry and Chemistry, The Graduate Center, City University of New York, New York, New York 10021, United States
| | - Rebecca L. Meshaw
- Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, United States
| | - Ganesan Vaidyanathan
- Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, United States
| | - Mike A. Cornejo
- Hunter College, City University of New York, New York, New York 10021, United States
- Ph.D. Programs in Biochemistry and Chemistry, The Graduate Center, City University of New York, New York, New York 10021, United States
| | - Brian M. Zeglis
- Hunter College, City University of New York, New York, New York 10021, United States
- Ph.D. Programs in Biochemistry and Chemistry, The Graduate Center, City University of New York, New York, New York 10021, United States
| | - Michael R. Zalutsky
- Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, United States
| |
Collapse
|
4
|
Liu L, Maurice R, Galland N, Moisy P, Champion J, Montavon G. Pourbaix Diagram of Astatine Revisited: Experimental Investigations. Inorg Chem 2022; 61:13462-13470. [PMID: 35977097 DOI: 10.1021/acs.inorgchem.2c01918] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The Pourbaix diagram of an element displays its stable chemical forms with respect to the redox potential and pH of the solution, whose knowledge is fundamental for understanding and anticipating the chemistry of the element in a specified solution. Unlike most halogens, the Pourbaix diagram in the aqueous phase for astatine (At, Z = 85) is still under construction. In particular, the predominant domains of two astatine species assumed to exist under alkaline conditions, At- and AtO(OH)2-, need to be refined. Through high-performance ion-exchange chromatography, electromobility measurements, and competition experiments, the existence of At- and AtO(OH)2- has been confirmed and the associated standard potential has been determined for the first time (0.86 ± 0.05 V vs the standard hydrogen electrode). On the basis of these results, a revised version of astatine's Pourbaix diagram is proposed, covering the three oxidation states of astatine that exist in the thermodynamic stability range of water: At(-I), At(I), and At(III) (as At-, At+, AtO+, AtO(OH), and AtO(OH)2-).
Collapse
Affiliation(s)
- Lu Liu
- IMT Atlantique, Nantes Université, CNRS, SUBATECH, F-44000 Nantes, France
| | - Rémi Maurice
- IMT Atlantique, Nantes Université, CNRS, SUBATECH, F-44000 Nantes, France.,Univ Rennes, CNRS, ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, 35000 Rennes, France
| | - Nicolas Galland
- Nantes Université, CNRS, CEISAM UMR 6230, F-44000 Nantes, France
| | - Philippe Moisy
- CEA, DES, ISEC, DMRC, Univ Montpellier, F-30207 Marcoule, France
| | - Julie Champion
- IMT Atlantique, Nantes Université, CNRS, SUBATECH, F-44000 Nantes, France
| | - Gilles Montavon
- IMT Atlantique, Nantes Université, CNRS, SUBATECH, F-44000 Nantes, France
| |
Collapse
|
5
|
Recent progress of astatine-211 in endoradiotherapy: Great advances from fundamental properties to targeted radiopharmaceuticals. CHINESE CHEM LETT 2022. [DOI: 10.1016/j.cclet.2022.03.025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
6
|
Separation, speciation, and mechanism of astatine and bismuth extraction from nitric acid into 1-octanol and methyl anthranilate. Sep Purif Technol 2022. [DOI: 10.1016/j.seppur.2021.120088] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
7
|
Radiolabeling chemistry with heavy halogens iodine and astatine. Nucl Med Mol Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00013-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Guérard F, Maingueneau C, Liu L, Eychenne R, Gestin JF, Montavon G, Galland N. Advances in the Chemistry of Astatine and Implications for the Development of Radiopharmaceuticals. Acc Chem Res 2021; 54:3264-3275. [PMID: 34350753 DOI: 10.1021/acs.accounts.1c00327] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
ConspectusAstatine (At) is the rarest on Earth of all naturally occurring elements, situated below iodine in the periodic table. While only short-lived isotopes (t1/2 ≤ 8.1 h) are known, 211At is the object of growing attention due to its emission of high-energy alpha particles. Such radiation is highly efficient to eradicate disseminated tumors, provided that the radionuclide is attached to a cancer-targeting molecule. The interest in applications of 211At in nuclear medicine translates into the increasing number of cyclotrons able to produce it. Yet, many challenges related to the minute amounts of available astatine are to be overcome in order to characterize its physical and chemical properties. This point is of paramount importance to develop synthetic strategies and solve the labeling instability in current approaches that limits the use of 211At-labeled radiopharmaceuticals. Despite its discovery in the 1940s, only the past decade has seen a significant rise in the understanding of astatine's basic chemical and radiochemical properties, thanks to the development of new analytical and computational tools.In this Account, we give a concise summary of recent advances in the determination of the physicochemical properties of astatine, putting in perspective the duality of this element which exhibits the characteristics both of a halogen and of a metal. Striking features were evidenced in the recent determination of its Pourbaix diagram such as the identification of stable cationic species, At+ and AtO+, contrasting with other halogens. Like metals, these species were shown to form complexes with anionic ligands and to exhibit a particular affinity for organic species bearing soft donor atoms. On the other hand, astatine shares many characteristics with other halogen elements. For instance, the At- species exists in water, but with the least range of EH-pH stability in the halogen series. Astatine can form molecular interactions through halogen bonding, and it was only recently identified as the strongest halogen-bond donor. This ability is nonetheless affected by relativistic effects, which translate to other peculiarities for this heavy element. For instance, the spin-orbit coupling boosts astatine's propensity to form charge-shift bonds, catching up with the behavior of the lightest halogens (fluorine, chlorine).All these new data have an impact on the development of radiolabeling strategies to turn 211At into radiopharmaceuticals. Inspired by the chemistry of iodine, the chemical approaches have sparsely evolved over the past decades and have long been limited to electrophilic halodemetalation reactions to form astatoaryl compounds. Conversely, recent developments have favored the use of the more stable At- species including the aromatic nucleophilic substitution with diaryliodonium salts or the copper-catalyzed halodeboronation of arylboron precursors. However, it is clear that new bonding modalities are necessary to improve the in vivo stability of 211At-labeled aryl compounds. The tools and data gathered over the past decade will contribute to instigate original strategies for overcoming the challenges offered by this enigmatic element. Alternatives to the C-At bond such as the B-At and the metal-At bonds are typical examples of exciting new axes of research.
Collapse
Affiliation(s)
- François Guérard
- Université de Nantes, CNRS, Inserm, CRCINA, F-44000 Nantes, France
| | | | - Lu Liu
- IMT-Atlantique Bretagne-Pays de la Loire - Nantes Campus, SUBATECH, UMR CNRS 6457, F-44000 Nantes, France
| | - Romain Eychenne
- Université de Nantes, CNRS, Inserm, CRCINA, F-44000 Nantes, France
- Arronax GIP, F-44817 Saint-Herblain, France
| | | | - Gilles Montavon
- IMT-Atlantique Bretagne-Pays de la Loire - Nantes Campus, SUBATECH, UMR CNRS 6457, F-44000 Nantes, France
| | - Nicolas Galland
- Université de Nantes, CNRS, CEISAM UMR 6230, F-44000 Nantes, France
| |
Collapse
|
9
|
Berdal M, Gouard S, Eychenne R, Marionneau-Lambot S, Croyal M, Faivre-Chauvet A, Chérel M, Gaschet J, Gestin JF, Guérard F. Investigation on the reactivity of nucleophilic radiohalogens with arylboronic acids in water: access to an efficient single-step method for the radioiodination and astatination of antibodies. Chem Sci 2020; 12:1458-1468. [PMID: 34163909 PMCID: PMC8179031 DOI: 10.1039/d0sc05191h] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Easy access to radioiodinated and 211At-labelled bio(macro)molecules is essential to develop new strategies in nuclear imaging and targeted radionuclide therapy of cancers. Yet, the labelling of complex molecules with heavy radiohalogens is often poorly effective due to the multiple steps and intermediate purifications needed. Herein, we investigate the potential of arylboron chemistry as an alternative approach for the late stage labelling of antibodies. The reactivity of a model precursor, 4-chlorobenzeneboronic acid (1) with nucleophilic iodine-125 and astatine-211 was at first investigated in aqueous conditions. In the presence of a copper(ii) catalyst and 1,10-phenanthroline, quantitative radiochemical yields (RCYs) were achieved within 30 minutes at room temperature. The optimum conditions were then applied to a CD138 targeting monoclonal antibody (mAb) that has previously been validated for imaging and therapy in a preclinical model of multiple myeloma. RCYs remained high (>80% for 125I-labelling and >95% for 211At-labelling), and the whole procedure led to increased specific activities within less time in comparison with previously reported methods. Biodistribution study in mice indicated that targeting properties of the radiolabelled mAb were well preserved, leading to a high tumour uptake in a CD138 expressing tumour model. The possibility of divergent synthesis from a common modified carrier protein demonstrated herein opens facilitated perspectives in radiotheranostic applications with the radioiodine/211At pairs. Overall, the possibility to develop radiolabelling kits offered by this procedure should facilitate its translation to clinical applications. The high reactivity of astatine and iodine in water with arylboronic acids provides access to an efficient single-step antibody radiolabelling.![]()
Collapse
Affiliation(s)
- Marion Berdal
- Université de Nantes, CNRS, Inserm, CRCINA F-44000 Nantes France
| | - Sébastien Gouard
- Université de Nantes, CNRS, Inserm, CRCINA F-44000 Nantes France
| | - Romain Eychenne
- Université de Nantes, CNRS, Inserm, CRCINA F-44000 Nantes France .,Arronax GIP Saint-Herblain France
| | - Séverine Marionneau-Lambot
- Université de Nantes, CNRS, Inserm, CRCINA F-44000 Nantes France .,Department of Nuclear Medicine, CHU Nantes Nantes France
| | - Mikaël Croyal
- CRNH-O, Mass Spectrometry Core Facility F-44000 Nantes France.,NUN, INRA, CHU Nantes, UMR 1280, PhAN, IMAD, CRNH-O F-44000 Nantes France
| | - Alain Faivre-Chauvet
- Université de Nantes, CNRS, Inserm, CRCINA F-44000 Nantes France .,Department of Nuclear Medicine, CHU Nantes Nantes France
| | - Michel Chérel
- Université de Nantes, CNRS, Inserm, CRCINA F-44000 Nantes France .,ICO-René Gauducheau Saint-Herblain France
| | - Joëlle Gaschet
- Université de Nantes, CNRS, Inserm, CRCINA F-44000 Nantes France
| | | | - François Guérard
- Université de Nantes, CNRS, Inserm, CRCINA F-44000 Nantes France
| |
Collapse
|